ABSTRACT
PURPOSE Identification of discrete sub-groups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children’s Oncology Group biology study AEWS18B1-Q was to perform molecular characterization of a large cohort of patients with localized Ewing sarcoma treated on prospective trials with modern standard of care therapy.
METHODS We analyzed clinical and molecular features from patients with localized EWS enrolled on AEWS0031, AEWS1031, or INT-0154 frontline trials. All patients had available FFPE tissue, frozen tissue, or whole-genome amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in TP53 and STAG2. Where available, tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses.
RESULTS Three hundred and fifty-one cases had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 cases (80.3%). Pathogenic mutations in TP53 and STAG2 were identified in 5.1% and 7.6% of cases, respectively and 63.1% of cases were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with TP53 mutation (5-year cumulative incidence of relapse 43%, CI [17%, 67%] vs. 22%, CI [17%, 27%]; Gray’s test P = 0.039), STAG2 mutation (53%, CI [29%, 73%] vs. 21%, CI [16%, 26%]; P < 0.001), and recurrent CNAs (30%, CI [22%, 37%] vs. 16%, CI [9%, 24%]; P = 0.005). In a multivariable analysis, STAG2 mutation was the only molecular biomarker that remained prognostic.
CONCLUSION This is a prospective validation of the molecular prognostic features of localized EWS receiving standard of care therapy on therapeutic clinical trials. Building on prior work, patients with STAG2 mutations were at high risk of relapse.
Key Objective To determine if molecular features can identify clinically relevant disease sub-groups applicable to frontline clinical trial design among patients with localized Ewing sarcoma.
Knowledge Generated Among 351 patients with localized Ewing sarcoma treated on prospective trials, canonical fusions were identified in 80% of cases. In a multivariable analysis of patients with genomically defined Ewing sarcoma, the presence of STAG2 mutations identified a high-risk population.
Relevance (added by Associate Editor)
Competing Interest Statement
RG has equity in Google, Microsoft, Amazon, Apple, Moderna, Pfizer, and Vertex Pharmaceuticals; his spouse is employed by Apree Health. DSS provides consulting services for Boehringer Ingelheim. NJD owns stock in CVS, GE Healthcare, and Johnson and Johnson. KMB is on the Data and Safety Monitoring Board for Merck. DRR is on the Data and Safety Monitoring Board for SpringWorks and Eisai. SGD reports consulting fees from Amgen, Bayer, EMD Serono, InhibRx, and Jazz and travel expenses from Loxo, Roche, and Salarius. LM has received consulting fees from Gilead and Novartis. BDC has equity in Acceleron Pharma; he holds consulting roles with PetDx, Animal Cancer Foundation, and the Osteosarcoma Institute; he has received research funding from Gradalis; his spouse is employed by and receives equity from Generate Biomedicines. KAJ has received honoraria from Foundation Medicine and Takeda; she holds consulting roles with Bayer and Ipsen; she has received travel reimbursement from Bayer.
Funding Statement
This work was supported by COG Biospecimen Bank Grant U24CA196173, the NCI K08 Career Development Award (RG), the DoD PRCRP Fellow Career Development Award (RG), the ASCO Career Development Award (RG), the Rally Foundation Career Development Award (RG), the Boston Childrens Hospital TRP Mentored Career Development Award (RG), the NCI 7U10CA180899-10 Childrens Oncology Group Statistics and Data Center (NJD, MDK, RH), the Pediatric Cancer Research Foundation (KK, JA, BDC), the St. Baldricks Foundation, the Childrens Oncology Group Reference Lab Grant, the Pan Mass Challenge Precision for Kids Team (KAJ), and the NCTN Operations Center Grant (U10CA180886).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the Dana-Farber Cancer Institute gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
